Last reviewed · How we verify
Experimental: Active "I-Reconstruction" Therapy
Ofloxacin ophthalmic solution is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death.
Ofloxacin ophthalmic solution is an antibiotic used to treat bacterial eye infections. It is effective against a range of susceptible bacteria but is contraindicated in patients with hypersensitivity to quinolones. Common side effects include transient ocular burning, stinging, redness, and itching. Drug interactions are primarily theoretical due to lack of specific studies, but caution is advised with theophylline, caffeine, warfarin, and cyclosporine. The drug is not currently generating revenue as it is experimental.
At a glance
| Generic name | Experimental: Active "I-Reconstruction" Therapy |
|---|---|
| Also known as | I-Reconstruction |
| Sponsor | International Association Psychosomatics And Health Therapy |
| Drug class | Fluoroquinolone |
| Target | DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ofloxacin works by interfering with the bacterial DNA replication process, which is essential for bacterial survival and proliferation.
Approved indications
Common side effects
- transient ocular burning or discomfort
- stinging
- redness
- itching
- chemical conjunctivitis/keratitis
- ocular/periocular/facial edema
- foreign body sensation
- photophobia
- blurred vision
- tearing
- dryness
- eye pain
Drug interactions
- Theophylline: Potential elevation of plasma concentrations
- Caffeine: Interference with metabolism
- Warfarin and derivatives: Enhanced anticoagulant effects
- Cyclosporine: Transient elevations in serum creatinine
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: